Complete Side Effect & Cost Breakdown: Making Your Choice
Wegovy Side Effects Compared to Mounjaro: Understanding Your Monthly Investment
The decision between Wegovy and Mounjaro involves balancing efficacy expectations, side effect tolerability, and long-term financial commitment. Wegovy's semaglutide mechanism targets GLP-1 receptors exclusively, typically producing gastrointestinal side effects in 20-30% of patients during dose escalation, including nausea, vomiting, and diarrhoea. Mounjaro's dual GIP/GLP-1 approach may offer different tolerability patterns, though both treatments share similar gastrointestinal profiles due to their appetite-regulating mechanisms.
From a cost perspective, your Wegovy journey requires careful budgeting across 16 weeks of dose escalation, starting at £79.99 monthly for the 0.25mg starter dose and progressing to £209.99 for the 2.4mg maintenance dose. This transparent pricing structure allows you to plan your annual weight management investment, particularly important given that weight management is a long-term commitment requiring sustained treatment for optimal results.
UK Monthly Cost Analysis: Wegovy vs Mounjaro Treatment Investment
EverydayMeds offers competitive Wegovy pricing with our structured dose escalation: 0.25mg (weeks 1-4) at £79.99, 0.5mg (weeks 5-8) at £94.99, 1mg (weeks 9-12) at £99.99, 1.7mg (weeks 13-16) at £139.99, and maintenance 2.4mg from £209.99 monthly. New customers benefit from the FIRST40 discount code at checkout, while returning customers maintain affordability with DOSE25, ensuring predictable ongoing costs. Your complete escalation phase costs £624.96 over 16 weeks, then £209.99 monthly thereafter.
Our bundle options provide convenience for treatment continuity: the Intro Trio (0.25mg, 0.5mg & 1mg) costs £299.99, covering your first 12 weeks, while the Ultimate Stability Trio provides three months of maintenance 2.4mg supply for £649.99. These bundles eliminate the concern of supply interruptions and reduce ordering frequency, though individual pen purchases offer maximum flexibility for dose adjustments based on tolerability.
Clinical Evidence: Wegovy Side Effects Compared to Mounjaro Tolerability
In clinical trials, patients taking Wegovy alongside diet and exercise experienced predominantly gastrointestinal side effects, with nausea reported in approximately 44% of participants at the 2.4mg maintenance dose. The STEP trials demonstrated that most side effects were mild to moderate and decreased over time as patients adapted to treatment, particularly during the careful dose escalation protocol.
While head-to-head comparisons between Wegovy and Mounjaro aren't available due to different trial designs and populations, both medications show similar safety profiles reflecting their shared mechanism of slowing gastric emptying. The key difference lies in Mounjaro's dual receptor activation, which may influence individual tolerability patterns, though both require the same gradual dose escalation to minimise side effects.
How Wegovy Works: Understanding the Side Effect Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormones responsible for post-meal satiety signals. By activating GLP-1 receptors in the brain's appetite centres, Wegovy reduces food cravings and promotes feelings of fullness after smaller meals, supporting sustainable weight management alongside a reduced-calorie diet and increased physical activity. The medication also slows gastric emptying, which explains why gastrointestinal side effects are most common during treatment initiation. This mechanism differs from Mounjaro's dual GIP/GLP-1 activation, though both ultimately target similar appetite pathways. Understanding these mechanisms helps explain why both treatments share comparable side effect profiles, particularly the temporary digestive adjustments during dose escalation. The gradual dose increase protocol is specifically designed to allow your body to adapt to these changes, minimising treatment discontinuation due to tolerability issues.
Ordering Process: Starting Your Wegovy vs Mounjaro Journey
Beginning treatment requires a comprehensive 3-minute online clinical assessment reviewing your medical history, current medications, and weight management goals to determine suitability for either Wegovy or Mounjaro. Our prescribers, operating under GPhC registration #9012878, typically review assessments within 3 working days (express 24-hour service available), ensuring thorough evaluation of your individual circumstances and treatment preferences. Once approved, your prescription-only medicine arrives via next-day cold-chain delivery, maintaining the required 2-8°C temperature throughout transit to preserve medication integrity. Our clinical team remains available throughout your treatment to address side effect concerns, dose escalation queries, and comparative questions about Wegovy versus Mounjaro effectiveness. This ongoing support proves particularly valuable during the initial weeks when side effects are most likely to occur, ensuring you receive expert guidance on managing any temporary digestive adjustments.
Storage & Practical Considerations: Wegovy vs Mounjaro Convenience
Wegovy offers a storage advantage over Mounjaro, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications use similar injection devices, though Wegovy's FlexTouch pen system provides consistent dose delivery throughout the escalation protocol from 0.25mg to 2.4mg maintenance. The weekly injection schedule remains identical for both treatments, requiring the same commitment to consistent administration timing for optimal appetite regulation. Proper storage becomes particularly important given the monthly costs involved – a single pen represents significant investment, making temperature maintenance crucial for medication efficacy. Both treatments require identical dose escalation approaches, though Wegovy's established protocol provides extensive clinical experience in managing side effect progression during the 16-week titration period.
Budgeting for Long-Term Treatment: Wegovy Side Effects Compared to Mounjaro Value
Your annual Wegovy investment at maintenance dose totals approximately £2,519.88 (12 months at £209.99), excluding the initial escalation period, making financial planning essential for sustained weight management success. The front-loaded lower costs during escalation (£79.99-£139.99) provide time to assess tolerability before committing to the higher maintenance investment, allowing treatment discontinuation if side effects prove problematic. Understanding that weight regain occurs when treatment stops – with patients regaining approximately two-thirds of lost weight within one year of discontinuation according to STEP trial extensions – emphasises the importance of budgeting for long-term treatment rather than short-term trials.
Comparing monthly treatment costs between Wegovy and Mounjaro requires consideration of individual insurance coverage, private prescription costs, and ongoing availability, though both represent significant annual investments requiring careful financial planning. The DOSE25 returning customer discount ensures your maintenance phase remains affordable once established on treatment, while our bundle options provide cost predictability for multi-month treatment periods without frequent reordering requirements.
Expert Guidance on Treatment Selection: Weighing Wegovy vs Mounjaro
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns with your medical history, tolerance expectations, and budget considerations during the clinical assessment process. The choice between single GLP-1 activation (Wegovy) versus dual GIP/GLP-1 activation (Mounjaro) often depends on individual response patterns, previous treatment experiences, and specific side effect sensitivities that emerge during consultation. Our clinical team considers factors including your diabetes status, cardiovascular risk profile, and previous weight management attempts when recommending between these prescription-only medicines, ensuring personalised treatment selection rather than generic protocols. Given the substantial monthly investment required for either treatment, particularly at maintenance doses, our prescribers provide comprehensive counselling on realistic expectations, side effect management strategies, and long-term treatment planning. This expert guidance proves invaluable when weighing the comparative monthly costs against expected benefits, helping you make an informed decision that balances clinical effectiveness with financial sustainability throughout your weight management journey.
Ready to start your weight management journey? Complete our 3-minute clinical assessment to discuss whether Wegovy or Mounjaro suits your needs and budget, with treatment starting from £79.99 using code FIRST40 for new customers or DOSE25 for returning patients. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment with our GPhC-registered clinical team #9012878, who provide ongoing support throughout your treatment to ensure optimal results and side effect management. Our transparent pricing structure eliminates surprise costs, while our bundle options provide convenient multi-month supplies for uninterrupted treatment continuity. Weight management is a long-term commitment, and our clinical expertise ensures you receive the most appropriate treatment for your individual circumstances and financial considerations. Take the first step towards sustainable weight management with professional medical supervision and predictable monthly costs designed to support your long-term success.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
